References 1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. 2. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338. 3. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL: Epidermalgrowth- factor receptors and oestrogen receptors in human breast cancer. Lancet 1985, 1:364-366. 4. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of c-erbB2 in primary breast carcinomas: a study of 942 cases. Breast Cancer Res Treat 1995, 35:283-291. 5. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neuoncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993, 11:1936-1942. 6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al.: HER-2/neu gene amplification characterised by fluorescence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904. 7. Gee JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001, 95:247-254. 8. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ: Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000, 62:167-175. 9. Hermanto U, Zong CS, Wang LH: Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulinlike growth factor I-mediated mitogen-activated protein kinase activation. Cell Growth Differ 2000, 11:655-664. 10. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ER expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-1359. 11. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002, 13:65-72. 12. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003, 21:46-53. 13. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, et al.: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655. 14. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM: Estrogen receptor-positive, progesterone receptor- negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261. 15. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994, 54:2552-2555. 16. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995, 55:2279-2283. 17. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa J-PJ, Davidson NE: Methylation of estrogen and progesterone receptor genes 5' CpG islands correlates with ER and PgR gene expression in breast tumors. Clin Cancer Res 1996, 2:805-810. 18. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE: Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998, 58:2515-2519. 19. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr: Constitutive activation of NF-B during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997, 17:3629-3639. 20. Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-ęB. Mol Endocrinol 2004, 18:1396-1410. Breast Cancer Res. 2006;8(1) ©2006 BioMed Central, Ltd. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.